With the ability of viral infection to induce IFN secretion, promoting cell necrosis and the release of damage-associated molecular patterns (DAMPs), OVs are attractive as combination agents with other forms of tumor immunotherapy. The gene discussed is IFNA1; the disease is neoplasm.